ACE Inhibitors vs ARBs: Long-Term Cancer Risk Varies July 28, 2026

https://www.medscape.com/viewarticle/ace-inhibitors-vs-arbs-long-term-cancer-risk-varies-2026a1000pij?src= Patients treated exclusively with angiotensin-converting enzyme inhibitors (ACEIs) had lower overall cancer incidence than those treated exclusively with angiotensin receptor blockers (ARBs) over 23 years of follow-up. ACEI therapy was linked to lower odds for breast, prostate, melanoma, non-Hodgkin lymphoma, kidney, and colorectal cancers, but higher odds for lung, bladder, and pancreatic cancers.